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cost-effectiveness frontier generated by the average costs and benefits of each 
technology may mask inter-dependencies between technologies. Parameter val-
ues that render one technology efficient may render another inefficient, and vice 
versa. There can also be uncertainty about which interventions appear on the 
frontier, and the adoption of approaches to select competing interventions solely 
on the basis of being on the efficiency frontier may be unreasonable.
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Objectives: The ISPOR-SMDM Modeling Good Research Practices Task Force 
highlights the importance of model transparency and validation, including 
cross validation, as a means to establishing trust and confidence in economic 
models. (1) To investigate how a technical model validation can be conducted by 
reconstructing a previously-developed Microsoft Excel cost-effectiveness model 
using TreeAge; and, (2) to validate the model by comparing the results of two 
implementations. MethOds: An Excel-based cohort model on indolent NHL was 
reconstructed in in TreeAge using the same model structure, clinical inputs, and 
costing assumptions. Lifetime costs, life-years, quality-adjusted life-years, and 
incremental cost-effectiveness ratios (ICERs) were projected and compared for 
bendamustine-rituximab (Ben-R) versus fludarabine-rituximab (Fdb-R) in relapsed 
indolent NHL patients in Colombia. All costs were in 2013 Colombian pesos. The 
base-case results and sensitivity analyses were compared between the two soft-
ware tools and key implementation considerations were identified. Results: 
Key differences in the two software tools were identified and implementation 
differences will be described, including handling of survival inputs and applica-
tion of one-time and per-cycle costs. The TreeAge model produced more favorable 
results compared to the Excel model. The total costs for Ben-R and Fdb-R were 
$223,400,660 and $208,115,352 in the TreeAge model, respectively, while in the 
Excel model they were $291,192,912 and $260,463,392. The ICERs were $11,582,974/
LY and $13,815,417/QALY in the TreeAge model and $23,286,360/LY and $27,956,124/
QALY in the Excel model. However, once the differences between the two models 
were accounted for in implementation, the reconstructed TreeAge model produced 
approximately the same results compared to the original Excel model (23,381,795/
LY vs. $23,286,360/LY). cOnclusiOns: There are inherent differences in model 
implementation in Excel vs. TreeAge that should be considered when performing 
double implementation and when interpreting the model results. Model valida-
tion using two software tools is a practical way to ensure proper and intended 
implementation.
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Objectives: Different modeling approaches have been used to estimate the cost-
effectiveness of antipsychotics used to reduce psychotic symptoms of schizo-
phrenia. This study systematically reviewed schizophrenia modelling studies, to 
examine the relationship between the modeling approach used in schizophrenia 
studies and their reported outcomes. MethOds: A systematic literature review of 
MEDLINE, EconLit, Embase, and the Cochrane Library and an Internet search iden-
tified published results of schizophrenia modeling studies from 2000 to 2011. Two 
independent reviewers performed searches according to a prespecified protocol 
limited to English-language articles from any country. Results: Eighty-three pub-
lications reported 80 individual modelling studies that met the inclusion criteria. 
Fifty-seven studies reported results of 71 pairs of antipsychotic drug comparisons 
(drug A vs. drug B) as incremental cost-effectiveness ratios (ICERs), such as cost per 
quality-adjusted life-year (QALY), which allowed a comparison of results. The major-
ity of the economic evaluations used a Markov (23 studies) or decision-tree model 
23 studies); 9 studies used a discrete-event simulation (DES) model, and 2 studies used 
a microsimulation model. Among the 11 comparisons with contradictory results, we 
focused on the following drug comparisons of atypical antipsychotics with the most 
studies: risperidone long-acting injection versus oral olanzapine, oral risperidone ver-
sus oral olanzapine, oral risperidone or oral olanzapine versus ziprasidone, and oral 
olanzapine versus oral aripiprazole. Overall, model structure, time horizon, and patient 
population did not affect study results. Differences among studies with contradictory 
results generally reflected definition of response and relapse rates in the health states, 
validity of clinical data sources for transition probabilities, and assignment of utilities 
to estimate QALYs. cOnclusiOns: The cost-effectiveness results of the majority of 
models were in agreement regardless of the model structure. In models with contra-
dictory results, most differences could be explained by definition of response, relapse, 
discontinuation, or adverse-event rates and/or by the selection of sources.
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Objectives: A novel prognostic test is being developed to predict cancer-related 
mortality in early non-small cell lung cancer (NSCLC) to inform the use of adju-
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Objectives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
therapy escalation or intensification is often required to maintain acceptable 
levels of glycaemic control. The objective of this study was to assess how dif-
ferential dual therapy failure rates influence the cost effectiveness (CE) results in 
T2DM. MethOds: This study used the IMS Core Diabetes Model (CDM), a validated 
and established diabetes model, to evaluate the CE of metformin+ sulphonylurea 
(M+S) compared to metformin + DPP-4 (M+D). Efficacy data for dual therapy was 
sourced from a published systematic review; HbA1c and BMI change of -0.8% and 
0.199kg/m2 (M+D) and -0.79% and 0.707kg/m2 (M+S) respectively were applied. 
Rates of severe hypoglycaemia were 0.1612 and 1.538 per 100 patient years and 
4.596 and 68.769 per 100 patient years for non-severe events in M+D and M+S 
respectively. Insulin rescue therapy was initiated at an HbA1c threshold of 7.5%. 
Base case analysis assumed M+D and M+S had the same HbA1c durability; lifetime 
CE was assessed assuming improvement in durability favouring M+D applied 
in 10% increments with costs (US$) and benefits discounted at 3.5%. Results: 
In the base case analysis, annual HbA1c increase was 0.26% with mean time 
to therapy escalation of 5 years; and a predicted cost per quality adjusted life 
year (QALY) of $211,948. Mean annual increments in HbA1c for M+D of 0.182%, 
0.13% and 0.1% were necessary to achieve costs effectiveness at willingness to 
pay (WTP) thresholds of $100,000, $70,000 and $50,000 respectively. Published 
HbA1c durability for M+D of 0.052% per year was associated with a cost per QALY 
of $33,427. cOnclusiOns: This analysis demonstrates that the annual rate of 
increase in HbA1c exerts considerable influence over predicted CE and is therefore 
an important variable to study when assessing the CE of new interventions for 
the management of T2DM.
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The efficacy of plant sterols in reducing plasma LDL-cholesterol has been dem-
onstrated. In 2009, the European Food Safety Agency stated that for an intake of 
1.5-2.4g/day plant sterols, an average reduction of LDL blood cholesterol from 7% 
to 10.5% can be expected and such a reduction is of biological significance in terms 
of reduced risk of coronary heart disease. In France, the consumption of plant-
sterols enriched products (PSEP) was part of the official dietary recommendations 
for hypercholesterolemic subjects when the study was designed. Objectives: 
The objective was to assess the cost-effectiveness of a daily consumption of PSEP, 
in the context of a healthy diet, on statin’s initiation delay from the consumer 
perspective, in the eligibleat risk French population. MethOds: A 1 year cycle 
Markov model was built to estimate the benefit (i.e. delay/avoid statins’ initiation) 
in a French population aged between 45 and 65 years and at risk of drug treatment 
according to the French Drug Agency recommendations. Information on the evolu-
tion of cholesterol level and the different cardiovascular disease risk factors was 
retrieved in the literature. Costs of statin treatment duration avoidance (i.e. price 
of PSEP fully paid by the consumers) was estimated according to age and gen-
der. Results: The eligiblepopulation included in the model was respectively 49% 
and 66% among the French male and female population between [45;65 y]. Based 
on the selected assumptions, and assuming that healthy diet is already integrated 
in lifestyle habits, daily cost per statin free life year due to substitution of usual 
dairy product by a PSEP was estimated at 0.71€ /day and 1.01€ /day respectively for 
male and female. cOnclusiOns: This exploratory work allowed getting a first 
estimation of the cost-effectiveness of the daily consumption of PSEP, from the 
consumer perspective in accordance with official dietary recommendations for 
cholesterol management.
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Objectives: The cost-effectiveness efficiency frontier is typically generated by 
plotting the costs and benefits for a variety of technologies, often summarised 
as the mean across a large number of simulations. However, the mean across 
simulations may mask correlations between technologies within simulations. We 
sought to investigate these issues using a HTA comparing 19 different interven-
tions. MethOds: We compared 19 different breast cancer surveillance strategies 
for women aged less than 50 years with a BRCA1 mutation. We calculated the 
cost-effectiveness efficiency frontier for 5,000 simulations and also based on the 
mean costs and benefits for each strategy. We also investigated the probability 
of a strategy appearing on the frontier and correlations between whether or not 
different strategies appeared on the frontier. Results: The efficiency frontier 
based on means included 6 strategies. This was the cost-effectiveness efficiency 
frontier in only 22 (0.44%) of 5,000 simulations. Forty four other frontiers were more 
likely to be generated by simulations. Two strategies not on the frontier of means 
had a substantial probability of being on the frontier. Some strategies were nega-
tively correlated such that the appearance of one strategy on the frontier never 
or seldom co-occurred with another. These negative correlations also occurred 
between strategies that appeared on the frontier of means. cOnclusiOns: The 
